Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Hemifacial Spasm
NCT00276315Phase 3Completed
- Sponsor
- Ipsen
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of abobotulinumtoxinA in hemifacial spasm (HFS) (2 arms), sponsored by Ipsen. Primary endpoint: Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels) at 4 weeks. Started Dec 2005; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
hemifacial spasm (HFS)
Beyond the preview
Go deeper on NCT00276315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276315.